NASDAQ:SWAVShockwave Medical Stock Price, Forecast & News

Shockwave Medical's stock was trading at $34.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SWAV stock has increased by 48.9% and is now trading at $51.29.
View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Shockwave Medical.

Shockwave Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Shockwave Medical.

Shockwave Medical will be holding an earnings conference call on Tuesday, August 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Shockwave Medical Inc (NASDAQ:SWAV) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.10. The company earned $15.20 million during the quarter, compared to analyst estimates of $14.17 million. Shockwave Medical had a negative return on equity of 38.18% and a negative net margin of 112.25%. Shockwave Medical's revenue for the quarter was up 109.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.37) earnings per share.
View Shockwave Medical's earnings history.

7 brokers have issued 12-month price objectives for Shockwave Medical's shares. Their forecasts range from $23.00 to $54.00. On average, they anticipate Shockwave Medical's stock price to reach $44.86 in the next twelve months. This suggests that the stock has a possible downside of 12.5%.
View analysts' price targets for Shockwave Medical.

Press coverage about SWAV stock has been trending very positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Shockwave Medical earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.
View the latest news about Shockwave Medical.

Shockwave Medical saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 3,960,000 shares, an increase of 6.2% from the July 15th total of 3,730,000 shares. Based on an average daily trading volume, of 405,900 shares, the days-to-cover ratio is currently 9.8 days. Currently, 14.9% of the shares of the stock are short sold.
View Shockwave Medical's Current Options Chain.

Some companies that are related to Shockwave Medical include Hill-Rom (HRC), Globus Medical (GMED), Irhythm Technologies (IRTC), Nevro (NVRO), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Inari Medical (NARI), Inspire Medical Systems (INSP), NuVasive (NUVA), Merit Medical Systems (MMSI), Cantel Medical (CMD), Glaukos (GKOS) and AtriCure (ATRC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), salesforce.com (CRM), Alibaba Group (BABA), Walt Disney (DIS), Trade Desk (TTD), Roku (ROKU), Paypal (PYPL), Square (SQ), Twilio (TWLO) and Shopify (SHOP).

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Shockwave Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (1.82%), Rhenman & Partners Asset Management AB (0.19%), Swiss National Bank (0.17%), First Trust Advisors LP (0.17%), UBS Group AG (0.09%) and SG Americas Securities LLC (0.05%). Company insiders that own Shockwave Medical stock include Antoine Papiernik, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, James E Flynn and Sofinnova Capital Vii Fcpr.
View institutional ownership trends for Shockwave Medical.

SWAV stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, First Trust Advisors LP, Swiss National Bank, Principal Financial Group Inc., SG Americas Securities LLC, Arizona State Retirement System, Jennison Associates LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Shockwave Medical.

Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SWAV stock can currently be purchased for approximately $51.29.

Shockwave Medical has a market capitalization of $1.63 billion and generates $42.93 million in revenue each year. The company earns $-51,110,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Shockwave Medical employs 162 workers across the globe.

The official website for Shockwave Medical is www.shockwavemedical.com.

Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected]